A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...